New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
16:16 EDTNBIXNeurocrine Biosciences announces VMAT2 inhibitor granted two more patents
Neurocrine Biosciences announced that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, or VMAT2. European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. The United States Patent and Trademark Office recently granted a second patent. United States Patent Number 8,357,697 covers the method of treating hyperkinetic movement disorders using NBI-98854 and will expire in November 2027.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2015
07:12 EDTNBIXNeurocrine coverage assumed with a Buy at Jefferies
Jefferies assumed coverage on Neurocrine with a Buy rating and increased its price target to $61 from $39. The firm expects Neurocrine Phase III data for elagolix and valbenazine over the next 6-9 months, to drive potential regulatory approval and market launch in 2017.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use